SCHEMBL25534980

SCHEMBL25534980

c1ccc(-c2ccc(-c3nc(-c4cccc5ccccc45)cc(-c4ccc(-c5ccc6c(c5)-c5ccccc5C6(c5ccccc5)c5ccccc5)c5ccccc45)n3)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 4/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
MAPK1 P28482 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
MCL1 Q07820 1/20 0.36
ACMSD Q8TDX5 1/20 0.36
LMNA P02545 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25534966 0.99 MAPT (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535131 0.98 MAPT (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535051 0.97 CA12 (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535090 0.97 MAPT (0.37) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25538148 0.96 MAPT (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535005 0.96 MEN1 (0.40) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25538146 0.96 MEN1 (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534627 0.95 MAPT (0.39) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25535235 0.95 MAPT (0.36) MAPTALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL25534619 0.94 MAPT (0.40) MAPTALDH1A1HPGDKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167072-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE PIEZO1, LEF1, L1CAM MAPT 1595/4885ALDH1A1 254/4885HPGD 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.